Search

Your search keyword '"O'Reilly S"' showing total 40 results

Search Constraints

Start Over You searched for: Author "O'Reilly S" Remove constraint Author: "O'Reilly S" Journal annals of oncology Remove constraint Journal: annals of oncology
40 results on '"O'Reilly S"'

Search Results

1. Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

3. 1292P A review of in-hospital end-of-life care (EOLC) for oncology patients during the COVID-19 pandemic

6. 1493P An evaluation of the psychological impact of early phase clinical trials in cancer patients

17. The impact of the 21 gene recurrence score (RS) on chemotherapy (CHemoRx) prescribing in hormone receptor (HR) positive, lymph node positive (LN+) early-stage breast cancer (BC) in Ireland: A national, multi-centre, prospective study (CTRIAL-IE 15-34)

19. Oncotype DX score, menopausal status and body mass index

20. Do oncology patients understand clinical trials? A nationwide study by Cancer Trials Ireland

21. Decisions and supports around clinical trial participation: A national study by Cancer Trials Ireland

24. A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy

25. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as predictive biomarkers of pathologic complete response (pCR) in neoadjuvant breast cancer: an Irish Clinical Oncology Group study (ICORG 16-20)

26. 208P - The impact of the 21 gene recurrence score (RS) on chemotherapy (CHemoRx) prescribing in hormone receptor (HR) positive, lymph node positive (LN+) early-stage breast cancer (BC) in Ireland: A national, multi-centre, prospective study (CTRIAL-IE 15-34)

30. 1538P - Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as predictive biomarkers of pathologic complete response (pCR) in neoadjuvant breast cancer: an Irish Clinical Oncology Group study (ICORG 16-20)

32. 464PD - A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy

Catalog

Books, media, physical & digital resources